期刊文献+

常见非编码RNA的典型甲基化修饰在胃癌中的研究进展

Research Progress of Common Non-coding RNA′s Typical Methylation in Gastric Cancer
下载PDF
导出
摘要 胃癌是常见的消化道恶性肿瘤,严重威胁患者生命。近年来,随着非编码RNA(ncRNA)甲基化修饰在胃癌中的研究发现,ncRNA甲基化修饰影响细胞分化、血管生成、免疫反应、炎症反应等阶段,进而参与胃癌的发生发展、分化、侵袭转移及转归预后等环节。此外,ncRNA甲基化修饰具备差异性表达的特点,可以通过联合检测构建胃癌诊断和预后模型,具有成为胃癌分子标志物的巨大潜能。深入研究甲基化修饰的机制和表达特点,发掘分子生物学应用于胃癌的临床价值,可为胃癌的诊疗提供新思路。 Gastric cancer is a common malignant tumor of digestive system,seriously threatening the patients′lives.In recent years,with the development of studies on non-coding RNA(ncRNA)methylation in gastric cancer,researchers have found that ncRNA methylation affects cell differentiation,angiogenesis,immune response,inflammation and other phases.And ncRNA methylation is further involved in the development,differentiation,invasion,metastasis,prognosis and other processes.And ncRNA methylation modification has the characteristics of differential expression,which can be used to construct a diagnosis and prognosis model of gastric cancer through combined detection,and has great potential to become a molecular marker of gastric cancer.Further study on the mechanism and expression characteristics of methylation modification and exploring the clinical value of molecular biology in gastric cancer can provide new ideas for the diagnosis and treatment of gastric cancer.
作者 赵乔飞 查文章 周勇 张业鹏 ZHAO Qiaofei;ZHA Wenzhang;ZHOU Yong;ZHANG Yepeng(The Yancheng Clinical College of Xuzhou Medical University,Yancheng 224000,China;Department of General Surgery,Yancheng NO.1 People′s Hospital,Yancheng 224000,China;Department of General Surgery,the Fourth Affiliated Hospital of Nantong University,Yancheng 224000,China)
出处 《医学综述》 CAS 2023年第17期3389-3393,3399,共6页 Medical Recapitulate
基金 江苏省卫生健康委员会医学科研面上项目(M2020100)。
关键词 胃癌 非编码RNA 甲基化修饰 Gastric cancer Non-coding RNA Methylation modification
  • 相关文献

参考文献3

二级参考文献25

  • 1Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225-262.
  • 2Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future, lnt J Biol Markers 2001; 16:73-86.
  • 3Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J lntern Med 2007; 18:175-184.
  • 4Roulston JE. Limitations of tumour markers in screening. Br J Surg 1990; 77:961-962.
  • 5Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
  • 6Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
  • 7Chen C, Ridzon DA, Broomer A J, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
  • 8Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9.
  • 9Hafner M, Landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008; 44:3-12.
  • 10Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-2261.

共引文献1452

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部